AbbVie | ABBV - Gross Profit On Sales

Stock Price
223.52
Daily Change
4.50 2.05%
Monthly
-4.24%
Yearly
17.27%
Q1 Forecast
216.14

AbbVie reported $10.47B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Abbott USD 6.54B 625M Dec/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eisai JPY 151.84B 8.21B Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
J&J USD 16.6B 118M Dec/2025
Medtronic USD 5.44B 123M Sep/2025
Merck USD 13.42B 431M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 2.46B 520M Dec/2024
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025
Zoetis USD 1.72B 96M Sep/2025